Skip to main content
Erschienen in: Tumor Biology 3/2016

30.09.2015 | Original Article

PMS2 expression in epithelial ovarian cancer is posttranslationally regulated by Akt and essential for platinum-induced apoptosis

verfasst von: Jinghui Jia, Zehua Wang, Jing Cai, Yuan Zhang

Erschienen in: Tumor Biology | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Epithelial ovarian cancer (EOC) is the most lethal of the gynecologic malignancies, mainly due to the advanced stage at diagnosis and development of cisplatin resistance. The sensitivity of tumor cells to cisplatin is frequently affected by defect in DNA mismatch repair (MMR), which repairs mispaired DNA sequences and regulates DNA-damage-induced apoptosis. However, the role of postmeiotic segregation increased 2 (PMS2), a member of MMR protein family, in cisplatin resistance remains elusive. In the present study, we demonstrated the frequent deficiency of PMS2 and phosphorylation of Akt in EOC cell lines and tissues. Results of complex immunoprecipitation (co-IP) and protein stability assay indicated that activated Akt could directly bind to PMS2 and cause degradation of PMS2 in EOC cells. In addition, functional experiments revealed that PMS2 was required for cisplatin-induced apoptosis and cell cycle arrest in G2/M phase. These findings provide a novel insight into molecular mechanisms linking MMR with chemoresistance and suggest that stabilization of PMS2 expression may be useful in overcoming the cisplatin resistance in EOC.
Literatur
1.
Zurück zum Zitat Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.CrossRefPubMed Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.CrossRefPubMed
2.
Zurück zum Zitat Suryadi J, Bierbach U. DNA metalating-intercalating hybrid agents for the treatment of chemoresistant cancers. Chemistry. 2012;18(41):12926–34.CrossRefPubMed Suryadi J, Bierbach U. DNA metalating-intercalating hybrid agents for the treatment of chemoresistant cancers. Chemistry. 2012;18(41):12926–34.CrossRefPubMed
3.
Zurück zum Zitat Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res. 2008;14(5):1291–5.CrossRefPubMed Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res. 2008;14(5):1291–5.CrossRefPubMed
4.
Zurück zum Zitat Borst P, Rottenberg S, Jonkers J. How do real tumors become resistant to cisplatin? Cell Cycle. 2008;7(10):1353–9.CrossRefPubMed Borst P, Rottenberg S, Jonkers J. How do real tumors become resistant to cisplatin? Cell Cycle. 2008;7(10):1353–9.CrossRefPubMed
5.
Zurück zum Zitat Jiricny J. The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol. 2006;7(5):335–46.CrossRefPubMed Jiricny J. The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol. 2006;7(5):335–46.CrossRefPubMed
6.
Zurück zum Zitat Kothandapani A, Sawant A, Dangeti VS, Sobol RW, Patrick SM. Epistatic role of base excision repair and mismatch repair pathways in mediating cisplatin cytotoxicity. Nucleic Acids Res. 2013;41(15):7332–43.CrossRefPubMedPubMedCentral Kothandapani A, Sawant A, Dangeti VS, Sobol RW, Patrick SM. Epistatic role of base excision repair and mismatch repair pathways in mediating cisplatin cytotoxicity. Nucleic Acids Res. 2013;41(15):7332–43.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat van Thuijl HF, Mazor T, Johnson BE, Fouse SD, Aihara K, Hong C, et al. Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment. Acta Neuropathol. 2015;129(4):597–607.CrossRefPubMedPubMedCentral van Thuijl HF, Mazor T, Johnson BE, Fouse SD, Aihara K, Hong C, et al. Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment. Acta Neuropathol. 2015;129(4):597–607.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Hamaya Y, Guarinos C, Tseng-Rogenski SS, Iwaizumi M, Das R, Jover R, et al. Efficacy of adjuvant 5-fluorouracil therapy for patients with EMAST-positive stage II/III colorectal cancer. PLoS ONE. 2015;10(5):e0127591.CrossRefPubMedPubMedCentral Hamaya Y, Guarinos C, Tseng-Rogenski SS, Iwaizumi M, Das R, Jover R, et al. Efficacy of adjuvant 5-fluorouracil therapy for patients with EMAST-positive stage II/III colorectal cancer. PLoS ONE. 2015;10(5):e0127591.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Peltomaki P. Deficient DNA, mismatch repair: a common etiologic factor for colon cancer. Hum Mol Genet. 2001;10(7):735–40.CrossRefPubMed Peltomaki P. Deficient DNA, mismatch repair: a common etiologic factor for colon cancer. Hum Mol Genet. 2001;10(7):735–40.CrossRefPubMed
10.
Zurück zum Zitat Drake AC, Campbell H, Porteous ME, Dunlop MG. The contribution of DNA mismatch repair gene defects to the burden of gynecological cancer. Int J Gynecol Cancer. 2003;13(3):262–77.CrossRefPubMed Drake AC, Campbell H, Porteous ME, Dunlop MG. The contribution of DNA mismatch repair gene defects to the burden of gynecological cancer. Int J Gynecol Cancer. 2003;13(3):262–77.CrossRefPubMed
13.
Zurück zum Zitat Perego P, Gatti L, Righetti SC, Beretta GL, Carenini N, Corna E, et al. Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells. Int J Cancer. 2003;105(5):617–24.CrossRefPubMed Perego P, Gatti L, Righetti SC, Beretta GL, Carenini N, Corna E, et al. Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells. Int J Cancer. 2003;105(5):617–24.CrossRefPubMed
14.
Zurück zum Zitat Liu LZ, Zhou XD, Qian G, Shi X, Fang J, Jiang BH. AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. Cancer Res. 2007;67(13):6325–32.CrossRefPubMed Liu LZ, Zhou XD, Qian G, Shi X, Fang J, Jiang BH. AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. Cancer Res. 2007;67(13):6325–32.CrossRefPubMed
15.
Zurück zum Zitat Geisler JP, Goodheart MJ, Sood AK, Holmes RJ, Hatterman-Zogg MA, Buller RE. Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma. Cancer. 2003;98(10):2199–206.CrossRefPubMed Geisler JP, Goodheart MJ, Sood AK, Holmes RJ, Hatterman-Zogg MA, Buller RE. Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma. Cancer. 2003;98(10):2199–206.CrossRefPubMed
16.
Zurück zum Zitat Ali AY, Kim JY, Pelletier JF, Vanderhyden BC, Bachvarov DR, Tsang BK. Akt confers cisplatin chemoresistance in human gynecological carcinoma cells by modulating PPM1D stability. Mol Carcinog 2014 Ali AY, Kim JY, Pelletier JF, Vanderhyden BC, Bachvarov DR, Tsang BK. Akt confers cisplatin chemoresistance in human gynecological carcinoma cells by modulating PPM1D stability. Mol Carcinog 2014
17.
Zurück zum Zitat Jia J, Zhang Y, Cai J, Wang J, Ding H, Zhou J, et al. A novel function of protein kinase B as an inducer of the mismatch repair gene hPMS2 degradation. Cell Signal. 2013;25(6):1498–504.CrossRefPubMed Jia J, Zhang Y, Cai J, Wang J, Ding H, Zhou J, et al. A novel function of protein kinase B as an inducer of the mismatch repair gene hPMS2 degradation. Cell Signal. 2013;25(6):1498–504.CrossRefPubMed
18.
Zurück zum Zitat Su CH, Wang CY, Lan KH, Li CP, Chao Y, Lin HC, et al. Akt phosphorylation at Thr308 and Ser473 is required for CHIP-mediated ubiquitination of the kinase. Cell Signal. 2011;23(11):1824–30.CrossRefPubMed Su CH, Wang CY, Lan KH, Li CP, Chao Y, Lin HC, et al. Akt phosphorylation at Thr308 and Ser473 is required for CHIP-mediated ubiquitination of the kinase. Cell Signal. 2011;23(11):1824–30.CrossRefPubMed
19.
Zurück zum Zitat Zhang L, Lee KC, Bhojani MS, Khan AP, Shilman A, Holland EC, et al. Molecular imaging of Akt kinase activity. Nat Med. 2007;13(9):1114–9.CrossRefPubMed Zhang L, Lee KC, Bhojani MS, Khan AP, Shilman A, Holland EC, et al. Molecular imaging of Akt kinase activity. Nat Med. 2007;13(9):1114–9.CrossRefPubMed
20.
Zurück zum Zitat Yang L, Dan HC, Sun M, Liu Q, Sun XM, Feldman RI, et al. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res. 2004;64(13):4394–9.CrossRefPubMed Yang L, Dan HC, Sun M, Liu Q, Sun XM, Feldman RI, et al. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res. 2004;64(13):4394–9.CrossRefPubMed
21.
Zurück zum Zitat Kolodner RD, Marsischky GT. Eukaryotic DNA mismatch repair. Curr Opin Genet Dev. 1999;9(1):89–96.CrossRefPubMed Kolodner RD, Marsischky GT. Eukaryotic DNA mismatch repair. Curr Opin Genet Dev. 1999;9(1):89–96.CrossRefPubMed
22.
Zurück zum Zitat Zhang Y, Shu YM, Wang SF, Da BH, Wang ZH, Li HB. Stabilization of mismatch repair gene PMS2 by glycogen synthase kinase 3beta is implicated in the treatment of cervical carcinoma. BMC Cancer. 2010;10:58.CrossRefPubMedPubMedCentral Zhang Y, Shu YM, Wang SF, Da BH, Wang ZH, Li HB. Stabilization of mismatch repair gene PMS2 by glycogen synthase kinase 3beta is implicated in the treatment of cervical carcinoma. BMC Cancer. 2010;10:58.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Soni A, Bansal A, Singh LC, Mishra AK, Majumdar M, Regina T, et al. Gene expression profile and mutational analysis of DNA mismatch repair genes in carcinoma prostate in Indian population. OMICS. 2011;15(5):319–24.CrossRefPubMed Soni A, Bansal A, Singh LC, Mishra AK, Majumdar M, Regina T, et al. Gene expression profile and mutational analysis of DNA mismatch repair genes in carcinoma prostate in Indian population. OMICS. 2011;15(5):319–24.CrossRefPubMed
24.
Zurück zum Zitat Collins SL, Herve R, Keevil CW, Blaydes JP, Webb JS. Down-regulation of DNA mismatch repair enhances initiation and growth of neuroblastoma and brain tumour multicellular spheroids. PLoS ONE. 2011;6(12):e28123.CrossRefPubMedPubMedCentral Collins SL, Herve R, Keevil CW, Blaydes JP, Webb JS. Down-regulation of DNA mismatch repair enhances initiation and growth of neuroblastoma and brain tumour multicellular spheroids. PLoS ONE. 2011;6(12):e28123.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Prahm KP, Karlsen MA, Hogdall E, Scheller NM, Lundvall L, Nedergaard L, et al. The prognostic value of dividing epithelial ovarian cancer into type I and type II tumors based on pathologic characteristics. Gynecol Oncol. 2015;136(2):205–11.CrossRefPubMed Prahm KP, Karlsen MA, Hogdall E, Scheller NM, Lundvall L, Nedergaard L, et al. The prognostic value of dividing epithelial ovarian cancer into type I and type II tumors based on pathologic characteristics. Gynecol Oncol. 2015;136(2):205–11.CrossRefPubMed
26.
Zurück zum Zitat Shih Ie M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004;164(5):1511–8.CrossRefPubMed Shih Ie M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004;164(5):1511–8.CrossRefPubMed
27.
Zurück zum Zitat Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 2007;33(1):9–23.CrossRefPubMed Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 2007;33(1):9–23.CrossRefPubMed
28.
Zurück zum Zitat Shimodaira H, Yoshioka-Yamashita A, Kolodner RD, Wang JY. Interaction of mismatch repair protein PMS2 and the p53-related transcription factor p73 in apoptosis response to cisplatin. Proc Natl Acad Sci U S A. 2003;100(5):2420–5.CrossRefPubMedPubMedCentral Shimodaira H, Yoshioka-Yamashita A, Kolodner RD, Wang JY. Interaction of mismatch repair protein PMS2 and the p53-related transcription factor p73 in apoptosis response to cisplatin. Proc Natl Acad Sci U S A. 2003;100(5):2420–5.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Matin RN, Chikh A, Chong SL, Mesher D, Graf M, Sanza P, et al. p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis. J Exp Med. 2013;210(3):581–603.CrossRefPubMedPubMedCentral Matin RN, Chikh A, Chong SL, Mesher D, Graf M, Sanza P, et al. p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis. J Exp Med. 2013;210(3):581–603.CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Huang Y, Sen T, Nagpal J, Upadhyay S, Trink B, Ratovitski E, et al. ATM kinase is a master switch for the Delta Np63 alpha phosphorylation/degradation in human head and neck squamous cell carcinoma cells upon DNA damage. Cell Cycle. 2008;7(18):2846–55.CrossRefPubMedPubMedCentral Huang Y, Sen T, Nagpal J, Upadhyay S, Trink B, Ratovitski E, et al. ATM kinase is a master switch for the Delta Np63 alpha phosphorylation/degradation in human head and neck squamous cell carcinoma cells upon DNA damage. Cell Cycle. 2008;7(18):2846–55.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Stojic L, Brun R, Jiricny J. Mismatch repair and DNA damage signalling. DNA Repair (Amst). 2004;3(8–9):1091–101.CrossRef Stojic L, Brun R, Jiricny J. Mismatch repair and DNA damage signalling. DNA Repair (Amst). 2004;3(8–9):1091–101.CrossRef
32.
Zurück zum Zitat Horibe S, Matsuda A, Tanahashi T, Inoue J, Kawauchi S, Mizuno S, et al. Cisplatin resistance in human lung cancer cells is linked with dysregulation of cell cycle associated proteins. Life Sci. 2015;124:31–40.CrossRefPubMed Horibe S, Matsuda A, Tanahashi T, Inoue J, Kawauchi S, Mizuno S, et al. Cisplatin resistance in human lung cancer cells is linked with dysregulation of cell cycle associated proteins. Life Sci. 2015;124:31–40.CrossRefPubMed
Metadaten
Titel
PMS2 expression in epithelial ovarian cancer is posttranslationally regulated by Akt and essential for platinum-induced apoptosis
verfasst von
Jinghui Jia
Zehua Wang
Jing Cai
Yuan Zhang
Publikationsdatum
30.09.2015
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 3/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4143-2

Weitere Artikel der Ausgabe 3/2016

Tumor Biology 3/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.